BI 201335 demonstrates potential to shorten HCV treatment duration while achieving high sustained virological response rates in difficult to treat patients

Data from SILEN-C1 and SILEN-C3 trial presented at AASLD - For media outside of the U.S.A only

San Francisco, USA and Ingelheim, Germany, 8th November 2011 – Boehringer Ingelheim today announced results from two Phase IIb studies evaluating the combination of the company’s next generation protease inhibitor, BI 201335, with pegylated interferon (PegIFN) and ribavirin (RBV) in treatment-naïve genotype 1 (GT1) hepatitis C (HCV) patients. 1,2 These data were presented in oral sessions at the American Association for the Study of Liver Diseases (AASLD) 2011 Liver Meeting in San Francisco, USA.

Data from the SILEN-C3 study showed the potential for BI 201335 to shorten patients’ treatment duration to 12 weeks and improve the likelihood of viral cure (sustained viral response; SVR) compared to the former traditional standard of care – 48 weeks of treatment with PegIFN/RBV alone. 1,3 Furthermore, the SILEN-C1 study demonstrated the ability for BI 201335 to improve SVR in traditionally difficult to treat populations. 4,5